ArticleCureus2025
The Perils of Ablative Stereotactic Radiosurgery for the Nucleus Accumbens: A Historical Perspective Urging Caution.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiomodulation-The Final Frontier of Radiosurgery?Brain sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decade, interest in lesion-based neuromodulation has experienced a resurgence fueled in large part by the noninvasive nature of new technologies, especially high-intensity focused ultrasound (HIFU). The noninvasiveness and relatively low cost of these outpatient methods are key attributes contributing to growing acceptance. A recent resurgent embrace of stereotactic radiosurgery (SRS) for brain lesioning, especially in the treatment of tremor via thalamotomy, builds on this new trend. While we believe this development for treating well-established movement (tremor) and behavioral (obsessive-compulsive) disorders is warranted and perhaps even applauded, we are worried that enthusiasm for lesioning using SRS may now be getting ahead of itself. This concern stems from the exuberance for using SRS to treat additional behavioral diseases, as showcased during the recent American Society for Radiation Oncology (ASTRO) 2025 meeting. The near giddiness observed in San Francisco regarding the use of SRS to treat patients with psychiatric disorders prompts us to write the present cautionary editorial. The aim of this editorial is to caution against premature clinical enthusiasm for using ablative SRS to target the nucleus accumbens (NAc) for psychiatric disorders. Our objectives are to (1) contextualize this proposal within the troubling history of psychosurgical overreach, (2) summarize the substantial neuroscientific and clinical risks inherent to NAc ablation, and (3) advocate for a strict, evidence-based, and ethically grounded approach that prioritizes reversible neuromodulation over irreversible lesioning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.